W T MOORE
Overview
Explore the profile of W T MOORE including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
525
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
WALTON W, Nguyen V, Butnev V, Singh V, MOORE W, Bousfield G
J Clin Endocrinol Metab
. 2001 Aug;
86(8):3675-85.
PMID: 11502795
Human FSH consists of a mixture of isoforms that can be separated on the basis of differences in negative charge conferred by variations in the numbers of sialic acid residues...
2.
Sarrias M, Franchini S, Canziani G, Argyropoulos E, MOORE W, Sahu A, et al.
J Immunol
. 2001 Jul;
167(3):1490-9.
PMID: 11466369
The molecular mechanisms involved in the interaction of complement receptor 2 (CR2) with its natural ligands iC3b and C3d are still not well understood. In addition, studies regarding the binding...
3.
Franchini S, Zarkadis I, Sfyroera G, Sahu A, MOORE W, Mastellos D, et al.
Dev Comp Immunol
. 2001 May;
25(5-6):419-30.
PMID: 11356221
To gain further insight into the evolutionary history of the complement proteins C3, C4, and C5 we have now cloned the fifth component of complement from a rainbow trout (Oncorhynchus...
4.
Guthridge J, Rakstang J, Young K, Hinshelwood J, Aslam M, Robertson A, et al.
Biochemistry
. 2001 May;
40(20):5931-41.
PMID: 11352728
Human complement receptor type 2 (CR2, CD21) is a cell surface receptor that binds three distinct ligands (complement C3d, Epstein-Barr virus gp350/220, and the low-affinity IgE receptor CD23) via the...
5.
Sahu A, Soulika A, Morikis D, Spruce L, MOORE W, Lambris J
J Immunol
. 2000 Aug;
165(5):2491-9.
PMID: 10946275
We have previously identified a 13-residue cyclic peptide, Compstatin, that binds to complement component C3 and inhibits complement activation. Herein, we describe the binding kinetics, structure-activity relationship, and biotransformation of...
6.
Fiane A, Mollnes T, Videm V, Hovig T, Hogasen K, Mellbye O, et al.
Xenotransplantation
. 1999 Oct;
6(1):52-65.
PMID: 10355733
Compstatin, a newly described C3-binding peptide, inhibits complement activation by blocking C3 convertase-mediated cleavage of C3. As the complement activation is an essential part of the rejection reaction, we evaluated...
7.
Fiane A, Mollnes T, Videm V, Hovig T, Hogasen K, Mellbye O, et al.
Transplant Proc
. 1999 Mar;
31(1-2):934-5.
PMID: 10083413
No abstract available.
8.
Sahu A, Sunyer J, MOORE W, Sarrias M, Soulika A, Lambris J
Immunol Res
. 1998 Feb;
17(1-2):109-21.
PMID: 9479573
The third component of the complement system, C3, is a common denominator in the activation of the classical, alternative, and lectin pathways. The ability of C3 molecule to interact with...
9.
Butney V, Gotschall R, Butnev V, BAKER V, MOORE W, Bousfield G
Biol Reprod
. 1998 Feb;
58(2):458-69.
PMID: 9475402
Hybrid hormones were created using combinations of equine (e) LH, eFSH, and eCG alpha- and beta-subunit preparations. The efficiency of eFSH beta association was highest with eLH alpha (64-72%) and...
10.
Whitbeck J, Peng C, Lou H, Xu R, Willis S, Ponce de Leon M, et al.
J Virol
. 1997 Aug;
71(8):6083-93.
PMID: 9223502
Glycoprotein D (gD) is a structural component of the herpes simplex virus (HSV) envelope which is essential for virus entry into host cells. Chinese hamster ovary (CHO-K1) cells are one...